(Total Views: 142)
Posted On: 06/07/2022 9:50:15 AM
Post# of 25476
$JUPW Jupiter Wellness' to Present JW-300 Topical Burn Treatment at SCALE 2022 Aesthetic Medicine, Plastic Surgery & Medical Dermatology Conference
JW-300 Demonstrated Efficacy in the Treatment of Developing Burns (sunburn) in a Double-Blinded Placebo-Controlled Clinical Trial
JUPITER, FL / ACCESSWIRE / May 4, 2022/Jupiter Wellness, Inc. (NASDAQ:JUPW) will present data for Jupiter's JW-300, a cannabidiol topical treatment for first degree burns, at SCALE 2022 Aesthetic Medicine, Plastic Surgery & Medical Dermatology Conference to take place May 11-15, 2022 in Nashville, Tennessee.
In a clinical trial of 36 patients, a controlled area of skin was exposed to UV irradiation. The percentage of subjects who experienced burns (measured by erythema) in patients treated with JW-300 was significantly lower (p=0.047) than in subjects who received the placebo lotion. The percent of subjects who were burned in the placebo arm was 61% compared to 27% in patients treated with JW-300. In addition, in patients (n=18) treated with JW-300, the average erythema score was 0.388 after radiation compared to 0.722 in the placebo arm (n=18).
https://finance.yahoo.com/news/jupiter-wellne...00385.html
JW-300 Demonstrated Efficacy in the Treatment of Developing Burns (sunburn) in a Double-Blinded Placebo-Controlled Clinical Trial
JUPITER, FL / ACCESSWIRE / May 4, 2022/Jupiter Wellness, Inc. (NASDAQ:JUPW) will present data for Jupiter's JW-300, a cannabidiol topical treatment for first degree burns, at SCALE 2022 Aesthetic Medicine, Plastic Surgery & Medical Dermatology Conference to take place May 11-15, 2022 in Nashville, Tennessee.
In a clinical trial of 36 patients, a controlled area of skin was exposed to UV irradiation. The percentage of subjects who experienced burns (measured by erythema) in patients treated with JW-300 was significantly lower (p=0.047) than in subjects who received the placebo lotion. The percent of subjects who were burned in the placebo arm was 61% compared to 27% in patients treated with JW-300. In addition, in patients (n=18) treated with JW-300, the average erythema score was 0.388 after radiation compared to 0.722 in the placebo arm (n=18).
https://finance.yahoo.com/news/jupiter-wellne...00385.html
(0)
(0)
